Consumer Non-Durables
Japan Tobacco Inc.
In the news
- Nakasone led Japan with strong hand in era of Reagan and Thatcher Nov 30, 2019
- Global funds set sights on Japan property market Aug 11, 2019
- Bangladesh enjoys foreign investment tailwind for economic boom Jul 12, 2019
- Nomura bows to proxy pressure on key appointment Jun 19, 2019
- Abe's corporate reform plan faces acid test at government-run companies Jun 11, 2019 See more articles on Japan Tobacco Inc.
Business Summary
Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following segments: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, Processed Food, and Other. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The Other segment includes real estate and the handling of corporate expenses relating to corporate communication and operation of the head office. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.
Financial Highlights
| Dec 2018 | JPY | USD |
| Revenue | 2,215.96B | 20,064.33M |
| Gross Profit | 1,195.57B | 10,825.28M |
| Operating income | 532,832M | 4,824.50M |
| Income before tax | 531,486M | 4,812.31M |
| Net income | 385,676M | 3,492.08M |
| EBITDA | 690,929M | 6,255.98M |
| Diluted EPS | 215.20 | 1.94 |
| Dividends Per Share | 150 | 1.35 |
| Total Assets | 5,461.40B | 49,778.06M |
| Total liabilities | 2,760.95B | 25,164.79M |
| Total equity | 2,630.59B | 23,976.61M |
| Operating cash flow | 461,389M | 4,177.62M |
| Currency in JPY | Currency in USD |
Historical Data
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | |
| Revenue | 2,871.95B | 2,252.88B | 2,143.28B | 2,139.65B | 2,215.96B |
| Gross Profit | 1,607.49B | 1,267.68B | 1,192.41B | 1,215.36B | 1,195.57B |
| Operating income | 743,190.14M | 591,831M | 535,001M | 526,027M | 532,832M |
| Income before tax | 659,314.35M | 558,732M | 571,748M | 538,532M | 531,486M |
| Net income | 483,890.79M | 398,454M | 421,695M | 392,409M | 385,676M |
| EBITDA | 904,732.40M | 730,032M | 675,146M | 670,864M | 690,929M |
| Diluted EPS | 279.19 | 270.37 | 235.33 | 218.97 | 215.20 |
| Dividends Per Share | 100 | 118 | 130 | 140 | 150 |
| Total Assets | 4,704.70B | 4,558.23B | 4,744.37B | 5,221.48B | 5,461.40B |
| Total liabilities | 2,082.20B | 2,036.71B | 2,216.33B | 2,379.45B | 2,760.95B |
| Total equity | 2,536.83B | 2,451.59B | 2,456.09B | 2,761.68B | 2,630.59B |
| Operating cash flow | 543,696M | 468,432M | 376,549M | 419,212M | 461,389M |
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | |
| Revenue | 27,132.29M | 18,608.90M | 19,724.90M | 19,081.27M | 20,064.33M |
| Gross Profit | 15,186.54M | 10,471.12M | 10,973.92M | 10,838.55M | 10,825.28M |
| Operating income | 7,021.16M | 4,888.54M | 4,923.67M | 4,691.07M | 4,824.50M |
| Income before tax | 6,228.76M | 4,615.14M | 5,261.86M | 4,802.58M | 4,812.31M |
| Net income | 4,571.47M | 3,291.24M | 3,880.90M | 3,499.47M | 3,492.08M |
| EBITDA | 8,547.30M | 6,030.09M | 6,213.44M | 5,982.71M | 6,255.98M |
| Diluted EPS | 2.63 | 2.23 | 2.16 | 1.95 | 1.94 |
| Dividends Per Share | 0.94 | 0.97 | 1.19 | 1.24 | 1.35 |
| Total Assets | 39,240.21M | 37,892.14M | 40,677.10M | 46,351.38M | 49,778.06M |
| Total liabilities | 17,366.88M | 16,930.97M | 19,002.29M | 21,122.55M | 25,164.79M |
| Total equity | 21,158.83M | 20,379.85M | 21,057.92M | 24,515.64M | 23,976.61M |
| Operating cash flow | 5,136.47M | 3,869.26M | 3,465.42M | 3,738.50M | 4,177.62M |
Valuation Measures
| Dec 2018 | |
| PER | 12.15 |
| ROA | 7.22% |
| ROE | 14.30% |
| Operating margin | 24.04% |
| Profit margin | 17.40% |
Key executives
- President, CEO & Representative Director: Masamichi Terabatake
- CFO, Representative Director & Executive VP: Naohiro Minami
- Executive Officer, Head-Research & Development: Hiroyuki Miki
- Director, Head-Compliance & General Affairs: Kazuhito Yamashita
- Representative Director, EVP & Head-Corporate: Kiyohide Hirowatari
Shareholders
- Government of Japan (33.3%)
- Japan Tobacco Inc. (11.3%)
- Nomura Asset Management Co., Ltd. (2.0%)
- The Vanguard Group, Inc. (1.6%)
- Mizuho Bank Pension Fund (1.1%)
- BlackRock Fund Advisors (1.0%)
- Daiwa Asset Management Co. Ltd. (0.9%)
- Nikko Asset Management Co., Ltd. (0.8%)
- Massachusetts Financial Services Co. (0.7%)
- Capital Research & Management Co. (World Investors) (0.4%)
Contact Details
- Website:http://www.jti.co.jp
- Address: 2-2-1 Toranomon, Minato-Ku, Tokyo, 105-8422, Japan
- Phone: +81.3.3582.3111
Related Companies
- JTI (RMS) Ltd.
- Emerging Products Holding BV
- JTI Business Services (Asia) Sdn. Bhd.
- JTI Processadora de Tabaco do Brasil Ltda.
- United Dhaka Tobacco Co. Ltd.
- PT Karyadibya Mahardhika
- PT Surya Mustika Nusantara
- Fluxo Brasil Distribuidora de Produtos SA
- Reynolds American, Inc. /Natural American Cigarettes 9/
- JTI Tutun Urunleri Sanayi AS
- JT International Group Holding BV
- Shanghai JS Foods Co. Ltd.
- Japan Tobacco (Hong Kong) Ltd.
- Logic Technology Development LLC
- JT International Co. Ukraine CJSC
- JTI Tutun Urunleri Pazarlama AS
- JT (UK) Ltd.
- Zandera Ltd.
- Al Nakhla Tobacco Free Zone SAE
- Batata SA /Subsdiaries (2)/
- Al Nakhla Tobacco Co. SAE
- JT International (Asia Pacific) Ltd.
- JT International (Philippines), Inc.
- Haggar Cigarette & Tobacco Factory Ltd. (South Sudan)
- Haggar Holding Co. /Sudan Cigarette & Tobacco Business (2)/
- National Tobacco Enterprise (Ethiopia) Share Co.
- JT International India Pvt Ltd.
- JT America, Inc.
- JT International Luxembourg SA
- JT International Hellas SA
Competitors
- British American Tobacco p.l.c.
- Imperial Brands PLC
- Eastern Company
- Philip Morris International Inc.
- Altria Group Inc
- Ajinomoto Co., Inc.
- Maruha Nichiro Corp.
- Nichirei Corporation
- Nissui Pharmaceutical Co., Ltd.
- British American Tobacco Malaysia Bhd.
- Electronic Cigarettes International Group Ltd.
- LT Group, Inc.
- KT & G Corporation
- 22nd Century Group, Inc.
- Akebia Therapeutics, Inc.
- Pieris Pharmaceuticals, Inc.
- Swedish Match AB
- Reata Pharmaceuticals, Inc. Class A
- FibroGen, Inc.
- Schweitzer-Mauduit International, Inc.
- Abivax SA
- JW Pharmaceutical Corporation
- NGM Biopharmaceuticals, Inc.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 6 Dec, 2019